Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (ORION)
PrOspective inteRventional Study Exploring the mIcrobiota recolONization in Steroid-Refractory Graft-versus-Host Disease Patients Receiving MaaT013
Sponsor: MaaT Pharma
Listed as NCT05017688, this NA trial focuses on Intestinal GVHD and Steroid Refractory GVHD and remains ongoing. Sponsored by MaaT Pharma, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Nov 2025 — Present [monthly]
Unknown NA
Status: Recruiting → Unknown
-
Sep 2024 — Nov 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Nov 2023 — Jul 2024 [monthly]
Recruiting NA
-
Sep 2023 — Nov 2023 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Jul 2022 — Sep 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Jul 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MaaT Pharma
For direct contact, visit the study record on ClinicalTrials.gov .